AC Immune (NASDAQ:ACIU) Shares Cross Below 50-Day Moving Average – Time to Sell?

AC Immune (NASDAQ:ACIU)’s share price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.80 and traded as low as $2.31. AC Immune shares last traded at $2.37, with a volume of 124,100 shares.

Analyst Ratings Changes

Several brokerages recently issued reports on ACIU. Jefferies Financial Group reissued a “buy” rating and set a $7.00 target price on shares of AC Immune in a report on Friday, March 13th. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of AC Immune in a report on Monday, May 4th. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. Finally, Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.50.

AC Immune Stock Up 1.3%

The company has a debt-to-equity ratio of 0.11, a current ratio of 0.87 and a quick ratio of 1.02. The business’s fifty day simple moving average is $2.80 and its two-hundred day simple moving average is $2.97. The company has a market cap of $241.20 million, a PE ratio of -2.89 and a beta of 1.59.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%. The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $0.33 million. On average, analysts predict that AC Immune will post -0.84 earnings per share for the current year.

Insider Activity

In other news, CEO Andrea Pfeifer sold 10,000 shares of AC Immune stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the sale, the chief executive officer owned 3,820,288 shares in the company, valued at $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of AC Immune

Several institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the period. EFG International AG acquired a new stake in shares of AC Immune in the fourth quarter valued at about $41,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune in the third quarter valued at about $48,000. Susquehanna International Group LLP acquired a new stake in shares of AC Immune in the third quarter valued at about $63,000. Finally, Sei Investments Co. acquired a new stake in shares of AC Immune in the second quarter valued at about $51,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.